These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 22320148)

  • 1. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
    COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
    Jones PW; Singh D; Bateman ED; Agusti A; Lamarca R; de Miquel G; Segarra R; Caracta C; Garcia Gil E
    Eur Respir J; 2012 Oct; 40(4):830-6. PubMed ID: 22441743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
    Rennard SI; Scanlon PD; Ferguson GT; Rekeda L; Maurer BT; Garcia Gil E; Caracta CF
    Clin Drug Investig; 2013 Dec; 33(12):893-904. PubMed ID: 24085591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD.
    Gelb AF; Tashkin DP; Make BJ; Zhong X; Garcia Gil E; Caracta C;
    Respir Med; 2013 Dec; 107(12):1957-65. PubMed ID: 23916502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
    Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
    Maltais F; Milot J
    Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
    Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population.
    Lee SH; Lee J; Yoo KH; Uh ST; Park MJ; Lee SY; Kim JY; Kim DK; Kim SJ; Lee KH; Yoo CG
    Respirology; 2015 Nov; 20(8):1222-8. PubMed ID: 26370136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPD.
    D'Urzo A; Kerwin E; Rennard S; He T; Gil EG; Caracta C
    COPD; 2013 Aug; 10(4):500-10. PubMed ID: 23679347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.
    Woods JA; Nealy KL; Barrons RW
    Ann Pharmacother; 2013; 47(7-8):1017-28. PubMed ID: 23737515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease.
    Jones PW; Rennard SI; Agusti A; Chanez P; Magnussen H; Fabbri L; Donohue JF; Bateman ED; Gross NJ; Lamarca R; Caracta C; Gil EG
    Respir Res; 2011 Apr; 12(1):55. PubMed ID: 21518460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
    Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E
    Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPD.
    Marth K; Schuller E; Pohl W
    Respir Med; 2015 May; 109(5):616-24. PubMed ID: 25796962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
    COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study.
    Beier J; Kirsten AM; Mróz R; Segarra R; Chuecos F; Caracta C; Gil EG
    COPD; 2013 Aug; 10(4):511-22. PubMed ID: 23819698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.
    Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.